Saturday 17 October 2026
Export NAMS’s income statement to Excel — free account
NewAmsterdam Pharma Company N.V.
NAMS Healthcare Biotechnology
NewAmsterdam Pharma Company N.V.’s revenue for fiscal 2025 (year ended December 2025) was $22.5 million, down 50.6% from fiscal 2024. In the quarter to June 2026, revenue fell 80.7%, EPS fell 246.7% and free cash flow fell 4.07%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
19.83
0.79
−3.83%
Follow NAMS
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
587.14 | 172.66 | 184.61 | 96.03 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(106.62) | (127.31) | (101.63) | (103.28) | |
P/B ratio |
6.62 | 5.86 | 6.08 | 4.65 | |
Price to Tangible BV |
6.63 | 5.86 | 6.08 | 4.65 | |
EV/Sales |
497.94 | 144.41 | 156.28 | 76.05 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(24.72) | (22.96) | (23.80) | (18.56) | |
EV/FCF |
(24.67) | (22.92) | (23.76) | (18.54) | |
Quick Ratio |
8.70 | 9.45 | 7.43 | 12.09 | |
Current Ratio |
9.03 | 9.76 | 7.88 | 12.57 | |
Net Debt/EBITDA |
9.80 | 10.92 | 9.67 | 12.79 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.01 | 0.03 | 0.03 | 0.06 | |
Operating CF/Net income |
0.61 | 0.63 | 0.55 | 0.46 | |
Capex/Depreciation |
(1.36) | (0.61) | (1.69) | (0.66) | |
Research and Development Expense of Revenue |
1,125.99% | 1,250.30% | 120,606.25% | 8,899.71% | |
Selling, General and Administrative Expense of Revenue |
726.61% | 771.41% | 85,681.25% | 7,045.98% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
496.65% | 592.17% | 43,821.88% | 4,313.22% | |
Graham Net Nets |
0.14 | 0.15 | 0.14 | 0.20 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(6.37%) | (5.59%) | (4.93%) | (7.21%) | |
Free Cash Flow Yield |
(3.44%) | (3.65%) | (3.56%) | (4.27%) | |
Revenue per Share |
0.03 | 0.03 | 0.00 | 0.00 | |
Operating CF per Share |
(0.32) | (0.25) | (0.35) | (0.28) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.32) | (0.25) | (0.35) | (0.28) | |
Cash per Share |
5.15 | 5.24 | 5.38 | 5.92 | |
Shareholders Equity per Share |
5.12 | 5.47 | 5.77 | 6.12 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.12 | 5.47 | 5.77 | 6.12 | |
Free Cash Flow |
(39.29) | (30.64) | (40.97) | (32.81) | |
Working Capital |
586.23 | 590.62 | 589.91 | 674.06 | |
Capital Expenditures |
(0.08) | (0.04) | (0.10) | (0.04) | |
Net Current Asset Value |
586.18 | 590.62 | 589.85 | 673.97 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.01 | 3.13 | 0.12 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
5.66 | 7.09 | 6.86 | 5.34 | |
Average Assets |
759.78 | 775.53 | 816.95 | 612.81 | |
Average Common Equity |
704.96 | 721.29 | 720.47 | 553.47 |
Columns are period end dates